A 52-year-old man from Delhi presents with a 2-month history of progressive weakness, bleeding gums, and recurrent infections. On examination, he has pallor, petechiae, and lymphadenopathy. Laboratory findings: Hemoglobin 6.8 g/dL, WBC 18,500/μL (with 35% blasts), platelets 32,000/μL. Bone marrow aspiration shows 42% blasts with Auer rods. Cytochemistry: MPO positive. What is the most appropriate next step in management?

Explanation

## Diagnosis and Management: Acute Myeloid Leukemia (AML) ### Diagnostic Confirmation **Key Point:** This patient has **acute myeloid leukemia (AML)** based on: - ≥20% blasts in bone marrow (42% blasts) - Auer rods (pathognomonic for AML) - MPO positivity (myeloid marker) - Pancytopenia with leukocytosis ### Why Immediate Chemotherapy Is Correct **High-Yield:** AML is a medical emergency. Once the diagnosis is confirmed (which it is, with morphology, cytochemistry, and Auer rods), **induction chemotherapy should begin immediately** without delay. The standard induction regimen is "7+3": cytarabine (7 days) + daunorubicin or idarubicin (3 days). **Clinical Pearl:** Waiting for cytogenetic analysis, while important for prognosis and risk stratification, should NOT delay the start of induction therapy. Cytogenetics are sent in parallel with chemotherapy initiation. ### Timing Is Critical ```mermaid flowchart TD A[Suspected AML]:::outcome --> B[Confirm diagnosis:<br/>Morphology, cytochemistry,<br/>flow cytometry]:::action B --> C{Diagnosis confirmed?}:::decision C -->|Yes| D[Send cytogenetics,<br/>molecular studies<br/>IN PARALLEL]:::action D --> E[Initiate induction<br/>chemotherapy immediately]:::action E --> F[Assess response at<br/>day 14 bone marrow]:::action F --> G{CR achieved?}:::decision G -->|Yes| H[Consolidation therapy<br/>+ risk-adapted strategy]:::action G -->|No| I[Salvage therapy or<br/>clinical trial]:::action ``` **Key Point:** Cytogenetics and molecular testing (FLT3-ITD, NPM1, TP53) are essential for **risk stratification and treatment planning** but are NOT prerequisites for starting chemotherapy. Delays in initiating therapy worsen outcomes. ### Why Each Alternative Is Wrong #### Supportive Care Pending Cytogenetics (Option B) **Warning:** This is a common trap. While cytogenetics are important, they should be obtained **in parallel with chemotherapy initiation**, not as a prerequisite. AML progresses rapidly; every week of delay significantly worsens prognosis. The patient is already showing signs of leukostasis risk (high WBC, blasts) and organ dysfunction. #### Splenectomy (Option C) **Reasoning:** Splenectomy has no role in AML management. It is indicated in immune-mediated thrombocytopenia (ITP), not in leukemia-induced thrombocytopenia. The low platelets here are due to marrow infiltration and consumption, not immune destruction. #### Hydroxyurea (Option D) **Clinical Pearl:** Hydroxyurea is a cytoreductive agent used in chronic myeloid leukemia (CML) and occasionally in acute leukemias with very high WBC counts to prevent leukostasis. However, it is NOT a substitute for definitive chemotherapy in AML. While this patient's WBC is elevated (18,500), it is not in the range requiring urgent cytoreduction (typically >100,000). Hydroxyurea would delay definitive therapy. ### Induction Chemotherapy Regimen **High-Yield:** Standard "7+3" induction: - **Cytarabine (Ara-C):** 100–200 mg/m² IV daily × 7 days - **Daunorubicin:** 60–90 mg/m² IV daily × 3 days (days 1–3) - Alternative anthracycline: Idarubicin 12 mg/m² daily × 3 days **Mnemonic:** "**7+3 = CR in 70%**" — approximately 70% of fit AML patients achieve complete remission with standard induction. ### Prognostic Factors (Obtained in Parallel) | Factor | Favorable | Unfavorable | |--------|-----------|-------------| | **Age** | <60 years | >60 years | | **Cytogenetics** | t(15;17), t(8;21), inv(16) | Complex, monosomy 7, TP53 mut | | **Molecular** | NPM1 mut (no FLT3-ITD) | FLT3-ITD, TP53, complex | | **Performance status** | ECOG 0–1 | ECOG 3–4 | **Key Point:** This patient's age (52) and good performance status (ambulatory, no organ failure mentioned) make him a candidate for intensive chemotherapy. ### Supportive Care During Induction **Clinical Pearl:** While chemotherapy is initiated, aggressive supportive care is essential: - Transfuse PRBCs to maintain Hb >8 g/dL - Transfuse platelets to maintain >10,000/μL (higher if bleeding or sepsis) - Broad-spectrum antibiotics for any fever - Allopurinol or febuxostat + hydration for tumor lysis syndrome prophylaxis - HLA-matched platelet transfusions if alloimmunized